Frosted branch angiitis is a rare condition that makes the blood vessels that supply the retina look like the frosted ...

In the QUASAR trial, the efficacy and safety of Eylea HD were compared to Eylea in treatment-naïve patients with macular edema secondary to retinal vein occlusion including central retinal vein ...

ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion.

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

In a recent study, the company and its partner Bayer compared Eylea HD to the original version of Eylea in patients with macular edema following retinal vein occlusion (RVO), a common cause of ...

Brown GC, Magargal LE, Shields JA, et al. Retinal arterial obstruction in children and young adults. Ophthalmology 1981;88:18–25. Rosenberg MA, Savino PJ, Glaser JS . A clinical analysis of ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

Regeneron Pharmaceuticals (REGN) expands its focus on eye care with the acquisition of Oxular, a U.K.-based biotech ...

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Retinal Vein Occlusion Treatment Market by Treatment Type (Anti-VEGF Injection, Corticosteroid Treatment, Laser Therapy), Age Group (40-60, Above 60, ...

Injection 8 mg to treat patients with macular edema following retinal vein occlusion (RVO). The intended patient population includes those with central, branch and hemiretinal vein occlusions.